Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)

Background: There are limited real-world studies on the differences in leukotriene receptor antagonists (LTRA), H1-antihistamines (H1-AH), and inhaled corticosteroids (ICS) associated neuropsychiatric events. In this study, we aimed to analyze the characteristics of drug associated neuropsychiatric...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sainan Bian, Lisha Li, Zixi Wang, Le Cui, Yingyang Xu, Kai Guan, Bin Zhao, Lianglu Wang, Jia Yin
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Neuropsychiatric event Leukotriene receptor antagonist Antihistamine Inhaled corticosteroid Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/78ff2ed840ab4f5d87cf64e8d178e0e0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78ff2ed840ab4f5d87cf64e8d178e0e0
record_format	dspace
spelling	oai:doaj.org-article:78ff2ed840ab4f5d87cf64e8d178e0e02021-11-12T04:30:18ZNeuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)1939-455110.1016/j.waojou.2021.100594https://doaj.org/article/78ff2ed840ab4f5d87cf64e8d178e0e02021-10-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1939455121000880https://doaj.org/toc/1939-4551Background: There are limited real-world studies on the differences in leukotriene receptor antagonists (LTRA), H1-antihistamines (H1-AH), and inhaled corticosteroids (ICS) associated neuropsychiatric events. In this study, we aimed to analyze the characteristics of drug associated neuropsychiatric events, and compare the differences among different drug categories. Methods: Disproportionality analysis and Bayesian analysis were used in data mining to identify suspected neuropsychiatric events associated with LTRA, H1-AH, and ICS based on the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from January 2004 to September 2020. Demographic information, time interval to onset, and death rates of LTRA, H1-AH, and ICS-associated neuropsychiatric events were also analyzed. Results: A total of 9475 neuropsychiatric events were identified. The number of neuropsychiatric events related to LTRA, H1-AH, and ICS were 5201 (54.89%), 3226 (34.05%), and 1048 (11.06%), respectively. LTRA related neuropsychiatric events were more common in patients aged 4–6 years (18.66%). H1-AH and ICS related neuropsychiatric events were more common in patients aged 18–44 years (29.92%) and older than 65 years (30.60%), respectively. Montelukast was highly associated with neuropsychiatric events, with a high reporting odds ratio (ROR). Most neuropsychiatric symptoms occurred within the first 10 days after drug initiation (78.63% for LTRA, 91.39% for H1-AH, and 84.07% for ICS). The death rate due to neuropsychiatric events of first generation H1-AH was significantly higher than that of LTRA and ICS (p < 0.001). Conclusions: LTRA associated neuropsychiatric events reported in FAERS were most frequent in 4 to 6-year-old children. Most reported cases occurred within the first 10 days after drug initiation. The second generation H1-AH was relatively safe for neuropsychiatric events compared with the first generation. The fatality rate due to first generation H1-AH associated neuropsychiatric events was higher than that of LTRA and ICS. More attention should be paid to specific patients treated with LTRA and H1-AH.Sainan BianLisha LiZixi WangLe CuiYingyang XuKai GuanBin ZhaoLianglu WangJia YinElsevierarticleNeuropsychiatric eventLeukotriene receptor antagonistAntihistamineInhaled corticosteroidImmunologic diseases. AllergyRC581-607ENWorld Allergy Organization Journal, Vol 14, Iss 10, Pp 100594- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neuropsychiatric event Leukotriene receptor antagonist Antihistamine Inhaled corticosteroid Immunologic diseases. Allergy RC581-607
spellingShingle	Neuropsychiatric event Leukotriene receptor antagonist Antihistamine Inhaled corticosteroid Immunologic diseases. Allergy RC581-607 Sainan Bian Lisha Li Zixi Wang Le Cui Yingyang Xu Kai Guan Bin Zhao Lianglu Wang Jia Yin Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
description	Background: There are limited real-world studies on the differences in leukotriene receptor antagonists (LTRA), H1-antihistamines (H1-AH), and inhaled corticosteroids (ICS) associated neuropsychiatric events. In this study, we aimed to analyze the characteristics of drug associated neuropsychiatric events, and compare the differences among different drug categories. Methods: Disproportionality analysis and Bayesian analysis were used in data mining to identify suspected neuropsychiatric events associated with LTRA, H1-AH, and ICS based on the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from January 2004 to September 2020. Demographic information, time interval to onset, and death rates of LTRA, H1-AH, and ICS-associated neuropsychiatric events were also analyzed. Results: A total of 9475 neuropsychiatric events were identified. The number of neuropsychiatric events related to LTRA, H1-AH, and ICS were 5201 (54.89%), 3226 (34.05%), and 1048 (11.06%), respectively. LTRA related neuropsychiatric events were more common in patients aged 4–6 years (18.66%). H1-AH and ICS related neuropsychiatric events were more common in patients aged 18–44 years (29.92%) and older than 65 years (30.60%), respectively. Montelukast was highly associated with neuropsychiatric events, with a high reporting odds ratio (ROR). Most neuropsychiatric symptoms occurred within the first 10 days after drug initiation (78.63% for LTRA, 91.39% for H1-AH, and 84.07% for ICS). The death rate due to neuropsychiatric events of first generation H1-AH was significantly higher than that of LTRA and ICS (p < 0.001). Conclusions: LTRA associated neuropsychiatric events reported in FAERS were most frequent in 4 to 6-year-old children. Most reported cases occurred within the first 10 days after drug initiation. The second generation H1-AH was relatively safe for neuropsychiatric events compared with the first generation. The fatality rate due to first generation H1-AH associated neuropsychiatric events was higher than that of LTRA and ICS. More attention should be paid to specific patients treated with LTRA and H1-AH.
format	article
author	Sainan Bian Lisha Li Zixi Wang Le Cui Yingyang Xu Kai Guan Bin Zhao Lianglu Wang Jia Yin
author_facet	Sainan Bian Lisha Li Zixi Wang Le Cui Yingyang Xu Kai Guan Bin Zhao Lianglu Wang Jia Yin
author_sort	Sainan Bian
title	Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
title_short	Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
title_full	Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
title_fullStr	Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
title_full_unstemmed	Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)
title_sort	neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: a real-world analysis of the food and drug administration (fda) adverse event reporting system (faers)
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/78ff2ed840ab4f5d87cf64e8d178e0e0
work_keys_str_mv	AT sainanbian neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT lishali neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT zixiwang neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT lecui neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT yingyangxu neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT kaiguan neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT binzhao neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT liangluwang neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers AT jiayin neuropsychiatricsidereactionsofleukotrienereceptorantagonistantihistamineandinhaledcorticosteroidarealworldanalysisofthefoodanddrugadministrationfdaadverseeventreportingsystemfaers
_version_	1718431297605468160

Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)

Ejemplares similares